![\"\"](\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/06\/fb32f8d745341e9605acd7f6c3998b73.jpeg\")
<\/p>\n <\/p>\n
BOSTON & SHANGHAI, June 01, 2026–(BUSINESS WIRE<\/a>)–Eccogene<\/a>, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that data from a Phase 1b study conducted in China evaluating elecoglipron (AZD5004\/ECC5004), an oral small-molecule GLP-1 receptor agonist, will be presented in a late-breaking poster presentation at the 2026 Scientific Sessions of the American Diabetes Association\u00ae (ADA). The ADA\u2019s 2026 Scientific Sessions will take place June 5-8 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.<\/p>\n In addition, AstraZeneca, who has in-licensed global rights to elecoglipron outside Greater China, will present Phase 2b data from two global studies of elecoglipron during an ADA symposium.<\/p>\n “We are excited to showcase the rapid progress of elecoglipron at the ADA\u2019s 2026 Scientific Sessions, marking a pivotal moment for Eccogene on the global stage,” said Jingye Zhou, Ph.D., Chief Executive Officer of Eccogene. “The presentation of our late-breaking Phase 1b data alongside AstraZeneca\u2019s Phase 2b symposium underscores the momentum behind this program. It is a testament to our shared commitment to advancing elecoglipron to deliver clinically meaningful results for patients worldwide.”<\/p>\n Eccogene Late-Breaking Poster Presentation<\/p>\n Poster Title: Safety, Tolerability, PK, and PD of Elecoglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Chinese Adults Living with Obesity or Overweight with or without Type 2 Diabetes AstraZeneca Symposium: Two Presentations Followed by Independent Commentary<\/p>\n Symposium Title: AZD5004, A Novel Oral Small Molecule GLP-1 Receptor Agonist: Overweight\/Obesity (VISTA) and Type 2 Diabetes (SOLSTICE) Phase 2 Trial Results Presentation 1: VISTA: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Participants Living with Obesity or Overweight with Comorbidity Presentation 2: SOLSTICE: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus Independent Commentary: 3:55 p.m. to 4:15 p.m. CT<\/p>\n ADA abstracts are expected to be available through the conference platform in accordance with ADA policies. Eccogene plans to make its poster available on the Company\u2019s website following the conference.<\/p>\n About Elecoglipron<\/p>\n Elecoglipron is an investigational oral, small-molecule GLP-1 receptor agonist discovered by Eccogene. It is designed to offer a convenient once-daily dosing regimen with no food- or water-related restrictions, which may help support patient adherence and broaden access. In November 2023, Eccogene entered into a global licensing agreement with AstraZeneca for elecoglipron, while retaining co-development and co-commercialization rights in Greater China.<\/p>\n About Eccogene<\/p>\n Eccogene is a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions. The Company\u2019s diverse pipeline leverages deep expertise in translational research and small molecule drug discovery to address high-impact diseases with significant unmet need. For more information, please visit www.eccogene.com<\/a> or follow the company on LinkedIn<\/a>.<\/p>\n View source version on businesswire.com: https:\/\/www.businesswire.com\/news\/home\/20260601751467\/en\/<\/a><\/p>\n Contacts<\/p>\n
Presenter: Jai Patel, MBBS, MRCP(UK), Chief Medical Officer, Eccogene Inc.
Date\/Time: Sunday, June 7, 2026, 12:30 p.m. to 1:30 p.m. CT
Location: Poster Hall (Halls D-E)
Poster Number: 2844-LB<\/p>\n
Date\/Time: Monday, June 8, 2026, 3:15 p.m. to 4:15 p.m. CT
Location: Great Hall A (Level 1)<\/p>\n
Time: 3:15 p.m. to 3:35 p.m. CT<\/p>\n
Time: 3:35 p.m. to 3:55 p.m. CT<\/p>\n